country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P9932

Copy Link Print Information

Obiltoxaximab

Name: Obiltoxaximab
Brand: MedChemExpress
SKU: HY-P9932
Price: 250.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: ETI 204)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 99.06%
CAS No.: 1351337-07-9
Masse moléculaire:145.5 kDa

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Obiltoxaximab Chemical Structure

CAS No.: 1351337-07-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Essai clinique
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Publications (1)
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

anthrax protective antigen

In Vivo

Obiltoxaximab (16 mg/kg, i.v., a single dose for 70 days) for simulated populations of healthy and infected humans is comparable in overall serum exposures in individual infected macaques following obiltoxaximab, similar results in rabbit experiments^[1].
Obiltoxaximab (16 mg/kg, i.m., 24, 48, 72 h prior to lethal challenge with B. anthracis spores) leads to 100% survival challenged with B. anthracis spores in cynomolgus macaques and prevents systemic bacteremia in the vast majority of animals^[2].
Obiltoxaximab (4 and 8 mg/kg, i.v. and i.m., a single dose for 9 h) postexposure prophylaxis (PEP) leads to 100% survival with the combination of Levofloxacin (HY-B0330) challenged with B. anthracis spores in rabbits^[2].
Obiltoxaximab (8 mg/kg, i.v., a single dose, 29 days) combined with antibiotics or Doxycycline (HY-N0565) lowers bacteremia levels in protective antigen (PA) of anthrax induced rabbits^[5].

Pharmacokinetics of intramuscular Obiltoxaximab^[2]

Study and dose (mg/kg)	Postchallenge dosing schedule	C_max (μg/mL)	T_max (days)	AUC_0-∞ (μg·day/mL)	T_1/2 (days)	CL /F(mL/day/kg)	V_z/F (mL/kg)
PEP 2
8	18 h	80.8	1.0	1030	7.50	7.76	84.0
8	24 h	86.5	1.0	788	5.20	10.2	76.2
16	18 h	165	1.0	2120	8.44	7.54	91.9
16	24 h	119	1.0	1990	9.85	8.03	114
PEP 3
16	24 h	142	1.0	2190	10.4	7.00	110
16	36 h	132	0.50	1540	7.09	10.0	106
16	48 h	104	3.0	2040	12.6	8.00	143

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Human, macaques and rabbits^[1]
Dosage:

16 mg/kg
Administration:

i.v., a single dose, 70 days
Result:

Overall serum exposures were comparable following obiltoxaximab in human, macaques and rabbits.

Animal Model:

Cynomolgus macaques^[2]
Dosage:

16 mg/kg
Administration:

i.m., 24, 48, 72 h prior to lethal challenge with B. anthracis spores
Result:

Resulted in transient low levels of bacteremia in several animals, resolving in all animals after day 4, and the majority of animals remained abacteremic until day 56.

Animal Model:

Rabbits^[2]
Dosage:

4 and 8 mg/kg
Administration:

i.v. and i.m. at 4 and 8 mg/kg, a single dose, 9 h
Result:

Effectiveness in the PEP setting was initially examined in rabbits.

Animal Model:

Protective antigen (PA) of anthrax induced rabbits^[5]
Dosage:

8 mg/kg
Administration:

i.v., a single dose, 29 days
Result:

Lowered bacteremia levels between days 1 and 2 combined with antibiotics, eliminated bacteremia levels combined with Doxycycline (HY-N0565) in protective antigen (PA) of anthrax induced rabbits.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

45025512 [NCBI]

Accession

P13423

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

Application

ELISA, FACS, Functional assay

Chemical Information

CAS No. 1351337-07-9
Appearance Liquid
Masse moléculaire 145.5 kDa
Color Colorless to light yellow
SMILES

[Obiltoxaximab]
Synonyms

ETI 204
Livraison

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (1)

All

Sort by:

Journal Impact Factor

PLoS Pathog

2026 Aug 14;22(8):e1014523. PMID: 42600039

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (266 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Références

[1]. Nagy CF, et al. Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule. Clin Transl Sci. 2017 Jan;10(1):12-19. [Content Brief]

[2]. Yamamoto BJ, et al. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5796-805. [Content Brief]

[3]. Hou A W, et al. Obiltoxaximab: adding to the treatment arsenal for Bacillus anthracis infection[J]. Annals of Pharmacotherapy, 2017, 51(10): 908-913. [Content Brief]

[4]. Yamamoto B J, et al. Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre-and postexposure prophylaxis in animal models of inhalational anthrax[J]. Antimicrobial agents and chemotherapy, 2016, 60(10): 5796-5805. [Content Brief]

[5]. Biron B, et al. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax[J]. Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Obiltoxaximab

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Essai clinique
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Publications (1)
Pureté et documentation
Références

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Obiltoxaximab

Publications Citing Use of MedChemExpress (MCE) Obiltoxaximab